Dr Reddy’s Laboratories (NSE: DRREDDY) reported its second-quarter financial results for the period ended September 30, 2021.
The company had total revenue of ₹57.6 billion with a growth of 18% year on year.
Dr Reddy’s reported a net profit of ₹9.92 billion or ₹59.65 per share compared to ₹7.62 billion or ₹45.83 in the same quarter of the previous year.
The global generics business posted a growth of 19% year on year. The Indian business saw sales jump 25% on-year to ₹11.4 billion.
“I am pleased with the improvement in the financial performance across our businesses. While we continue to strengthen our core businesses of generics and APIs, we are also making investments in our long-term growth drivers and deeper innovation capabilities,” said G.V. Prasad, co-chairman and managing director at Dr Reddy’s.